1. Introduction

This schematic illustrates the nanofluidic framework governing brain water metabolism within the neurovascular unit. Blood flow through the capillary is indicated by the red arrow, while aquaporin-4 (AQP4) channels localized on astrocytic end feet enveloping the capillary are represented by the dotted blue boundary, highlighting their critical role in transmembrane water exchange. The capillary is functionally subdivided into three distinct regions: the Filtration Section (FS), characterized by outward water flux (Jv); the Oscillatory Section (OS), where bidirectional flow (±Jv) occurs due to dynamic pressure gradients; and the Reabsorption Section (RS), marked by inward water movement (–Jv). These fluxes are governed by the interplay between hydrostatic pressures at the arterial (pa) and venular (pv) ends, oncotic pressures within the capillary (πC) and interstitial fluid (πISF) and the superimposed intracranial pulsatile force, f(t). The bracketed region denotes the brain’s nanofluidic domain, within which water transport is proposed to follow a slip-flow mechanism rather than classical diffusion-limited dynamics. This model integrates vascular, interstitial and astroglial components into a unified system regulating cerebral water homeostasis. Importantly, the schematic is conceptual and not drawn to scale. It serves to emphasize the mechanistic coupling between capillary hemodynamics, AQP4-mediated transport and nanofluidic principles offering a foundation for targeted pharmacological modulation of brain water metabolism.

Figure 1: Nanofluidic mechanism of brain water metabolism.

An interdisciplinary nanofluidic perspective offers a transformative framework for understanding brain water metabolism, revealing previously unrecognized mechanisms with significant physiological and clinical implications. By integrating nanofluidic theory with computational modeling, this work systematically investigates cerebral water dynamics and their coupling with vascular, cellular and systemic processes. The proposed model conceptualizes the brain extracellular space as a nanofluidic domain in which water transport is governed by slip-flow mechanisms rather than classical diffusion constraints. Within this framework, aquaporin-4 (AQP4), highly expressed in astrocytic endfeet surrounding cerebral capillaries, provides kinetic regulation of transmembrane water exchange. Fluid transfer between capillary blood and interstitial space is assumed to be isosmotic and driven by intracranial pulsatility, reflecting a dynamic interplay between hydrostatic, oncotic and rhythmic pressure forces. Computational simulations based on this model reveal several critical insights. AQP4 polarization significantly modulates radial water fluxes, while elevated intracranial and venous pressures markedly influence transcapillary exchange. Beyond water dynamics, the model enables quantitative analysis of mass transport processes, including oxygen, carbon dioxide and glucose delivery, thereby linking cerebral hydration to metabolic homeostasis. Notably, it also highlights a functional coupling between brain water metabolism and cardiac-driven pulsatility^1,2. Clinically, dysregulation of brain water metabolism underlies cerebral edema, a life-threatening condition associated with traumatic brain injury, stroke, hydrocephalus, tumors and systemic disorders. Despite its significance, effective therapeutic control remains limited, partly due to persistent conceptual controversies. Emerging evidence challenges the traditional emphasis on the choroid plexus, instead supporting a capillary-centric model of cerebral water exchange across the brain parenchyma. Within this context, AQP4 emerges as a critical molecular target for pharmacological intervention. Modulation of AQP4 activity offers a promising strategy for regulating blood brain barrier water permeability and mitigating pathological fluid accumulation. The presented nanofluidic model provides a mechanistic and quantitative platform for evaluating such therapeutic approaches, optimizing drug delivery strategies and advancing the treatment of brain water metabolism disorders. This work bridges fundamental neurobiology, biophysics and pharmacology, offering a unified and translational framework to resolve longstanding controversies and guide next-generation neurotherapeutic development. New knowledge makes it possible to outline promising approaches in the treatment of the brain water metabolism disorders. The pharmacological arsenal of medicines currently used to correct disorders of cerebral water metabolism and combat brain edema represents a complex, which includes means of osmotherapy (mannitol, hypertonic sodium chloride solution), diuretics (furosemide, bumetanide) and other drugs with different mechanisms of action (corticosteroids, testosterone, dexamethasone, propofol, piroxicam, acetazolamide, etc.). The osmotherapy is used to provide an osmotic pressure gradient between blood and the brain fluids and to ensure directed water flow from the brain tissues into the systemic circulation. Diuretics serve the same purpose. The success of osmotherapy depends on water permeability of the BBB controlled by AQP4. Numerous studies have shown that the level of expression and the degree of polarization of AQP4 in the BBB structures are labile and depend on many physiological factors. Significant changes in the activity of AQP4 are observed in pathologies^3,4. The concept according to which aquaporins present molecular targets for drugs is very attractive and practically important. In view of this, much research has been carried out to study the action of drugs on aquaporin activity.  The (Table 1) shows the effects of some drugs, used in the treatment brain edema and water metabolism disorders, on the activity of aquaporins AQP1 and AQP4.

Table 1:  Pharmacological modulators of AQP1 and AQP4 activity.

Pharmacological modulation of aquaporins represents a promising yet complex strategy for controlling brain water metabolism. Aquaporin activity is highly tissue-specific, with identical isoforms mediating distinct physiological functions across organs. For instance, inhibition of AQP1 enhances renal diuresis but does not significantly alter water permeability at the blood-brain barrier (BBB), underscoring the need for precise, context-dependent evaluation of aquaporin-targeted therapies^5,6. A critical challenge in this field is the effective delivery of pharmacological modulators to intracellular targets. Prodrug strategies have emerged as a viable solution, exemplified by acetoxymethyl derivatives of loop diuretics such as furosemide and bumetanide, which enhance cellular permeability and release active AQP4 antagonists upon bioconversion. These approaches offer new avenues for selectively modulating AQP4, the प्रमुख regulator of water exchange across astrocytic endfeet at the BBB. Within the nanofluidic framework of brain water metabolism, therapeutic strategies must be dynamically aligned with the stage of pathology. In early phases of cerebral edema, AQP4 inhibition may reduce water influx into brain tissue, thereby limiting edema progression and serving as a preventive preoperative strategy. Conversely, in established edema, inhibition of AQP4 may impede fluid clearance from the brain, diminish the efficacy of osmotherapy and worsen neurological outcomes. These findings highlight the necessity of phase-specific pharmacological intervention.  At a fundamental level, brain water metabolism remains a subject of theoretical controversy. The conventional diffusion-barrier model, which treats the extracellular space as a restrictive medium, contrasts sharply with the emerging nanofluidic paradigm that describes water movement as a slip-flow process within an integrated extracellular network. The latter framework preserves the kinetic relevance of AQP4 and provides a coherent explanation for experimentally observed water fluxes and transport phenomena^7,8.

2. Conclusion

Importantly, the nanofluidic model expands the therapeutic landscape by enabling targeted pharmacological control of water dynamics at the BBB. By reconciling biophysical mechanisms with molecular pharmacology, this approach offers a robust platform for the development of next-generation treatments for cerebral edema and related neurological disorders.

3. References

1.      Verkman AS. Aquaporins in clinical medicine. Annu Rev Med, 2012;63: 303-316.

2.      Papadopoulos MC, Verkman AS. Aquaporin-4 and brain edema. Pediatr Nephrol, 2007;22(6): 778-784.

3.      Iliff JJ, Wang M, Liao Y, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma. Sci Transl Med, 2012;4(147): 147.

4.      Nagelhus EA, Ottersen OP. Physiological roles of aquaporin-4 in brain. Physiol Rev, 2013;93(4): 1543-1562.

5.      Abbott NJ, Pizzo ME, Preston JE, Janigro D, Thorne RG. The blood–brain barrier in health and disease. Neurobiol Dis, 2018;107: 1-7.

6.      Badaut J, Fukuda AM, Jullienne A, Petry KG. Aquaporin and brain diseases. Biochim Biophys Acta, 2014;1840(5): 1554-1565.

7.      Tait MJ, Saadoun S, Bell BA, Papadopoulos MC. Water movements in the brain: role of aquaporins. Trends Neurosci, 2008;31(1): 37-43.

8.      Smith AJ, Verkman AS. Superresolution imaging of aquaporin-4 cluster size in astrocyte plasma membranes. Biophys J, 2015;108(10): 2513-2520.